Brief: TGA Says Provisional Approval Of Celltrion Healthcare Australia Pty Ltd COVID-19 Treatment, Regdanvimab
Dec 6 (Reuters) -
* AUSTRALIA'S TGA SAYS PROVISIONAL APPROVAL OF CELLTRION
HEALTHCARE AUSTRALIA PTY LTD COVID-19 TREATMENT, REGDANVIMAB
(REGKIRONA)
* TGA -REGKIRONA PROVISIONALLY APPROVED FOR INTRAVENOUS
TREATMENT
OF MILD-TO-MODERATE COVID-19 IN ADULT PATIENTS CONFIRMED TO BE
INFECTED WITH COVID-19
* TGA -REGDANVIMAB (REGKIRONA) IS NOT INTENDED TO BE USED AS
A
SUBSTITUTE FOR VACCINATION AGAINST COVID-19
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap